Kymera Therapeutics (KYMR) PT Raised to $39 at Credit Suisse
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $117.39 +2.60%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Credit Suisse analyst Richard Law raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $39.00 (from $32.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
- Chemtrade Logistics Income Fund (CHE-U:CN) (CGIFF) PT Raised to Cdn$18.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
